Drugs / MK-0472
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05853367 | Jul 2023 → Jun 2028 expected | metastatic neoplasm, neoplasm | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0472 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05853367 ↗ |
| Route | Oral | “MK-0472 via oral capsule” NCT05853367 ↗ |